CL2022000933A1 - Manejo temprano y prevención de sepsis y síndrome similar a sepsis - Google Patents
Manejo temprano y prevención de sepsis y síndrome similar a sepsisInfo
- Publication number
- CL2022000933A1 CL2022000933A1 CL2022000933A CL2022000933A CL2022000933A1 CL 2022000933 A1 CL2022000933 A1 CL 2022000933A1 CL 2022000933 A CL2022000933 A CL 2022000933A CL 2022000933 A CL2022000933 A CL 2022000933A CL 2022000933 A1 CL2022000933 A1 CL 2022000933A1
- Authority
- CL
- Chile
- Prior art keywords
- sepsis
- syndrome
- prevention
- neonatal
- pla2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para tratar sepsis, síndromes inflamatorios agudos tal como síndrome de respuesta inflamatoria sistémica (SIRS), ántrax y coronavirus de síndrome respiratorio agudo grave (SARS y SARSCoV2), síndrome de insuficiencia respiratoria aguda neonatal (ARDS neonatal) por inhibidores de PLA2 y/o metaloproteasa, en particular, en combinación con antibióticos. En las formas de realización, el inhibidor de PLA2 es varespladib, metil varespladib, AZD2716-R,S y LY433771, el inhibidor de metaloproteasa es Primomastat, Batimastat, marimastat o vornostat.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962915209P | 2019-10-15 | 2019-10-15 | |
US202062990020P | 2020-03-16 | 2020-03-16 | |
US202063017966P | 2020-04-30 | 2020-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000933A1 true CL2022000933A1 (es) | 2023-01-06 |
Family
ID=75538114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000933A CL2022000933A1 (es) | 2019-10-15 | 2022-04-13 | Manejo temprano y prevención de sepsis y síndrome similar a sepsis |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220370411A1 (es) |
EP (1) | EP4045026A4 (es) |
JP (1) | JP2023500791A (es) |
KR (1) | KR20220084122A (es) |
CN (1) | CN115379836A (es) |
AU (1) | AU2020366021A1 (es) |
BR (1) | BR112022007299A2 (es) |
CA (1) | CA3157854A1 (es) |
CL (1) | CL2022000933A1 (es) |
CR (1) | CR20220219A (es) |
IL (1) | IL292152A (es) |
MX (1) | MX2022004476A (es) |
WO (1) | WO2021076712A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4370546A1 (en) * | 2021-07-12 | 2024-05-22 | Ohio State Innovation Foundation | Compositions and treatments for coronavirus infections |
WO2023063325A1 (ja) * | 2021-10-11 | 2023-04-20 | 国立大学法人 東京大学 | 新型コロナウイルス(SARS-CoV-2)感染阻害剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
US20070231334A1 (en) * | 2004-09-24 | 2007-10-04 | Ken Alibek | Combination therapy for anthrax using antibiotics and protease inhibitors |
US10750739B2 (en) * | 2014-08-07 | 2020-08-25 | The General Hospital Corporation | Stabilization of whole blood samples |
WO2016069813A1 (en) * | 2014-10-29 | 2016-05-06 | Apt Therapeutics, Inc. | Adp'ase-enhanced apyrase therapy for wounds, microbial infection, sepsis, and heterotopic ossification |
MA40998A (fr) * | 2014-11-21 | 2017-09-26 | Ophirex Inc | Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés |
-
2020
- 2020-10-15 EP EP20877364.8A patent/EP4045026A4/en active Pending
- 2020-10-15 CA CA3157854A patent/CA3157854A1/en active Pending
- 2020-10-15 MX MX2022004476A patent/MX2022004476A/es unknown
- 2020-10-15 CN CN202080085146.4A patent/CN115379836A/zh active Pending
- 2020-10-15 KR KR1020227016285A patent/KR20220084122A/ko unknown
- 2020-10-15 JP JP2022522802A patent/JP2023500791A/ja active Pending
- 2020-10-15 US US17/767,173 patent/US20220370411A1/en active Pending
- 2020-10-15 BR BR112022007299A patent/BR112022007299A2/pt unknown
- 2020-10-15 AU AU2020366021A patent/AU2020366021A1/en active Pending
- 2020-10-15 WO PCT/US2020/055709 patent/WO2021076712A1/en unknown
-
2022
- 2022-04-13 CL CL2022000933A patent/CL2022000933A1/es unknown
- 2022-05-16 CR CR20220219A patent/CR20220219A/es unknown
- 2022-10-15 IL IL292152A patent/IL292152A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220084122A (ko) | 2022-06-21 |
CN115379836A (zh) | 2022-11-22 |
CR20220219A (es) | 2022-09-23 |
JP2023500791A (ja) | 2023-01-11 |
US20220370411A1 (en) | 2022-11-24 |
CA3157854A1 (en) | 2021-04-22 |
EP4045026A1 (en) | 2022-08-24 |
EP4045026A4 (en) | 2023-11-08 |
IL292152A (en) | 2022-06-01 |
AU2020366021A1 (en) | 2022-04-21 |
WO2021076712A1 (en) | 2021-04-22 |
MX2022004476A (es) | 2022-06-16 |
BR112022007299A2 (pt) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000933A1 (es) | Manejo temprano y prevención de sepsis y síndrome similar a sepsis | |
CO7151502A2 (es) | Compuestos que inhiben la actividad de catecol o- metiltransferasa | |
CO6382129A2 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes | |
ECSP13012559A (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas | |
NI201000103A (es) | Formas cristalinas de dimetoxi docetaxel y metodo para preparar el mismo. | |
CL2011000242A1 (es) | Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia. | |
CL2015002710A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. | |
ATE517107T1 (de) | Pyrrolopyrazinkinaseinhibitoren | |
BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
CO6300942A2 (es) | Piridinas y pirazinas como inhibidores de p13k | |
CR20140555A (es) | Peptidomimeticos de smac útiles como inhibidores de proteínas de apoptosis (iap) | |
CR20110135A (es) | INHIBIDORES DE cMET | |
SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
ATE522536T1 (de) | Pyrrolopyrazin-kinasehemmer | |
CO6640246A2 (es) | Forma cristalina del inhibidor sglt2 bencilbenceno | |
CR20160433A (es) | Nuevos compuestos | |
ATE522534T1 (de) | Pyrrolopyrazin-kinasehemmer | |
ECSP14004595A (es) | 2-tiopirimidinonas | |
SV2013004451A (es) | Compuestos y su uso | |
UY37764A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
CL2022001368A1 (es) | Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos | |
GT200600235A (es) | Penemes triciclicos de 6-alquilideno como inhibidores de beta-lactamasas clase d | |
AR098888A1 (es) | Composición para el cuidado oral | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
CU20160139A7 (es) | Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos |